Search Results


Your search for ASCO matches 17239 pages

Showing 151 - 200

AACR and MPM Oncology Charitable Foundation Announce Three Grants to Support Transformative Cancer Research

Three grants for research that could transform cancer therapies have been awarded by the AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants Program, an innovative partnership between the American Association for Cancer Research (AACR) and the UBS Oncology Impact Fund...

National Brain Tumor Society Launches DNA Damage Response Consortium With Yale Cancer Center

The National Brain Tumor Society (NBTS) announced the launch of its new flagship research initiative, the DNA Damage Response Consortium, in partnership with Yale Cancer Center. The consortium will bring together a diverse team of adult and pediatric researchers to advance a new class of potential...

breast cancer

Having Metastatic Breast Cancer Has Led Me to Focus on What Matters

Nothing can really prepare you for cancer, but it helped that I have dedicated my life in service to others as a minister and advocate for social justice and health equity in breast cancer survivorship. Before my own breast cancer diagnosis in 2016, I had spent years as a volunteer for several...

integrative oncology

Use of Traditional Chinese Medicine Herbal Formula Xiao Yao San to Relieve Depression and Anxiety

The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus on ...

A Lifetime of Pioneering Biologic Research Leads to a New History of Evolution

Although The Social Conquest of Earth was published a decade ago, it is worth revisiting, because, as oncology luminary Harold Varmus, MD, stressed: “It is a tour de force that we ignore at our planet’s peril.” Its author, Edward O. Wilson, PhD, known as “the father of sociobiology,” died at the...


Conundrums of SARS–CoV-2 Infection in Cancer Care

The ASCO Post is pleased to present the Hematology Expert Review, an occasional feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib, Kröger, and Mikulska focus on the challenges of providing cancer care amid the COVID-19 pandemic. Here they present two...

Jeffrey Peppercorn, MD, MPH, Named Editor-in-Chief of JCO Oncology Practice

Jeffrey Peppercorn, MD, MPH, has been appointed as the next Editor-in-Chief of the ASCO journal JCO Oncology Practice (JCO OP). The journal publishes impactful information and insights to keep oncology practice current on changes and challenges inherent in delivering equitable, high-quality...

Seven New Research Grants Awarded by The Prevent Cancer Foundation

The Prevent Cancer Foundation recently announced funding for seven scientists who are researching cancer prevention and early detection. Each scientist has been awarded $100,000 for 2 years. The following individuals are the 2022 research grantees: Sarah Bernhardt, PhD, Postdoctoral Fellow Oregon...

skin cancer

RELATIVITY-047: Relatlimab Plus Nivolumab Worthy of Further Study in Advanced Melanoma and Beyond

In the recently published results of the RELATIVITY-047 trial,1 summarized in this issue of The ASCO Post, the addition of relatlimab to nivolumab monotherapy was associated with improved progression-free survival compared with nivolumab alone in patients with previously untreated advanced,...

City of Hope Completes Strategic Acquisition of Cancer Treatment Centers of America

On February 2, 2022, City of Hope announced that it has completed its previously announced acquisition of Cancer Treatment Centers of America (CTCA), a network of oncology hospitals and outpatient care centers across the United States. City of Hope, in Duarte, California, now has expanded its...

The Hamoui Foundation and LUNGevity Foundation Present Awards for RET-Positive Lung Cancer Research

The Hamoui Foundation and LUNGevity Foundation recently announced the 2022 recipients of the first The Hamoui Foundation/LUNGevity Clinical Research Award for RET-Positive Lung Cancer. RET is a driver mutation found in approximately 1% to 2% of people with non–small cell lung cancer. The goal of...

American Cancer Society Awards $16 Million in Grants to Establish Cancer Health Equity Research Centers

The American Cancer Society has awarded more than $16 million in grants to establish Cancer Health Equity Research Centers (CHERC) at minority-serving institutions. The inaugural cohort of institutions includes the Arizona Board of Regents–University of Arizona, the University of Illinois at...

Improving Oral Anticancer Therapy Adherence, a Call to Action, and an Upcoming FDA-ASCO Workshop

In a recently published paper in the Journal of Clinical Oncology,1 R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, Atlanta, and coleagues reflected on the growth in availability of oral anticancer therapies over the past decade and noted that as these treatments are easy to take ...

colorectal cancer

Reid M. Ness, MD, MPH, on Colorectal Cancer: Updates in Screening Recommendations

Reid M. Ness, MD, MPH, of Vanderbilt-Ingram Cancer Center, discusses significant updates to the NCCN Clinical Practice Guidelines in Oncology for colorectal cancer screening: lowering the age from 50 to 45 for the initiation of average-risk screening for all combinations of race, ethnicity, and...

bladder cancer

Thomas W. Flaig, MD, on Bladder Cancer: New Treatment Options

Thomas W. Flaig, MD, of the University of Colorado Cancer Center, discusses the rapidly changing treatment landscape for patients with bladder cancer, including PD-1 and PD-L1 inhibitors now approved for urothelial carcinoma; a category 1 indication for pembrolizumab in metastatic disease,...

pancreatic cancer

Margaret A. Tempero, MD, on Pancreatic Adenocarcinoma: Emerging Systemic Therapy Options

Margaret A. Tempero, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the most effective ways to use the regimens available to treat patients with pancreatic cancer (FOLFIRINOX [fluorouracil, leucovorin, irinotecan, and oxaliplatin] and...

bladder cancer

Expert Point of View: Guru P. Sonpavde, MD

Guru P. Sonpavde, MD, Director of the Bladder Cancer Program at Dana-Farber Cancer Institute, Boston, said the therapeutic landscape of urothelial cancer has been altered by PD-L1 inhibitors and antibody-drug conjugates. “The rationale for Cohort 3 was based on high response rates seen with a...

bladder cancer

Second-Line Combination Study in Urothelial Cancer

The combination of the antibody-drug conjugate sacituzumab govitecan-hziy and the immune checkpoint inhibitor pembrolizumab yielded antitumor activity as second-line therapy in patients with platinum-refractory, checkpoint inhibitor–naive, metastatic urothelial cancer, according to the results of...

pancreatic cancer

Screening Platform May Contribute to Detection of Early-Stage Pancreatic Cancers, Other Malignancies

A novel screening platform flagged more than 95% of stage I pancreatic cancers, in addition to other early-stage malignancies, according to a pilot study published by Hinestrosa et al in Nature Communications Medicine. If validated by future studies, the approach may offer a new way to detect the...

hematologic malignancies

Research Finds COVID-19 Vaccine Protects Most Patients With Cancer, but Risk Remains Higher for Patients With Blood Cancers

Using the nation’s largest COVID-19 data resource, a research team found that the COVID-19 vaccine offered protection for most patients with cancer. However, patients with certain types of cancer—especially those with hematologic malignancies—had a higher and widely varied risk of breakthrough...

breast cancer

Study Identifies Decline in Annual Screening for Breast Cancer Survivors

New research published by Lowry et al in JNCCN—Journal of the National Comprehensive Cancer Network found the rate of mammography participation by breast cancer survivors has been steadily declining since 2009, particularly among younger survivors. The researchers reviewed a nationwide commercial...

head and neck cancer

Expert Point of View: Gary Walker, MD, MPH, MS

Gary Walker, MD, MPH, MS, a head and neck radiation oncologist at Banner MD Anderson Cancer Center, Arizona, expressed concern about the disparities identified in the adoption of advanced radiation therapy techniques for patients with head and neck cancer. “Despite widespread availability of...

issues in oncology

Brazilian Oncologist Antônio Drauzio Varella, MD, Rises From the Streets of São Paulo to International Fame

In this edition of Living a Full Life, Guest Editor Jame Abraham, MD, spoke with Antônio Drauzio Varella, MD, a Brazilian oncologist, educator, scientist, and medical science popularizer in the press and television, as well as a best-selling author. Antônio Drauzio Varella, MD, was born in 1943 in ...

breast cancer

Study Finds Lumpectomy May Be as Effective as Mastectomy for Patients With Nonmetastatic Breast Cancer Younger Than 40

Young women with nonmetastatic breast cancer have similar survival rates whether they are treated with mastectomy or lumpectomy, despite tumors that are typically more aggressive and discovered at a later stage compared to their older counterparts. These findings were from a recent study examining...

breast cancer

Positive Lymph Nodes May Not Be an Indicator for Chemotherapy in Older Patients With Breast Cancer

Positive lymph node status may not be a reliable indicator of the need for adjuvant chemotherapy, and sentinel node biopsy may be unnecessary in older women with certain low-risk cancers, according to a new study presented by Nicholson et al at the American Society of Breast Surgeons 23rd Annual...

breast cancer

Study Finds COVID-19 Restrictions Delayed Breast Cancer Care at a Safety-Net Hospital

The 1-year local COVID-19 restrictions negatively impacted breast cancer stage at presentation, time to treatment, and time to surgery at an urban safety-net hospital, increasing the vulnerability of an already high-risk population. These findings were from a recent study presented by Kapp et al at ...


Protecting the Immunocompromised From COVID-19: Practical Information for Physicians

COVID-19 may have caught the world off guard in 2020, but in the 2 years since the pandemic began, several effective monoclonal antibodies and antiviral drugs have emerged to protect the most vulnerable patients. The ASCO Post spoke with Gunjan L. Shah, MD, a hematologic oncologist at Memorial...


FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum

On April 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to alpelisib (Vijoice) for adult and pediatric patients aged 2 years and older with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy. PROS encompasses a group of rare...

bladder cancer

Trials of PARP Inhibitors in Urothelial Cancer: More Questions Than Answers?

Two studies presented at the 2022 ASCO Genitourinary Cancers Symposium explored the role of poly (ADP-ribose) polymerase (PARP) inhibitors in urothelial cancer: ATLANTIS and BAYOU.1,2 Results suggest that PARP inhibitors may be useful in certain genetic subgroups and perhaps in combination with...

prostate cancer

Julio M. Pow-Sang, MD, on Nonmetastatic Prostate Cancer: Update on Best Management Practices

Julio M. Pow-Sang, MD, of Moffitt Cancer Center, discusses the treatment landscape for localized prostate cancer and its heterogeneity, the critical importance of stratifying risk to determining treatment options, and the continued improvement of therapy in the field.

thyroid cancer

Expert Point of View: Alexander T. Pearson, MD, PhD

Alexander T. Pearson, MD, PhD, Assistant Professor of Medicine at the University of Chicago, commended the artificial intelligence (AI)-augmented, ultrasound-based platform for screening and staging of thyroid cancer.  “In this study, Dr. Chan and colleagues processed high-resolution ultrasound...

colorectal cancer

Tumor Budding May Provide Independent Prognostic Value for Disease-Free and Overall Survival in Patients With Stage III Colon Cancer

Tumor budding is an emerging prognostic biomarker in colon cancer and currently influences decision-making in patients with pT1 and stage II colon cancer. In stage III colon cancer, its prognostic impact has been limited to small and retrospective cohorts. In a post hoc analysis of the IDEA-France...

gastrointestinal cancer

Study Explores Racial Disparities Among Patients Undergoing Gastrointestinal Cancer Surgery

Black adult patients are more likely than White patients to receive substandard gastrointestinal cancer surgery, according to a large study led by researchers at Yale Cancer Center published by Bakkila et al in JAMA Network Open. “The COVID-19 pandemic has brought to light previously reported race...

Norman Sharpless, MD, to Step Down as Director of the NCI

Norman E. Sharpless, MD, has announced that he has decided to step down from his position as Director of the National Cancer Institute (NCI), part of the National Institutes of Health, a position he has held since 2017. Dr. Sharpless will continue as NCI Director through April 29, 2022, to allow...


FDA Approves Axicabtagene Ciloleucel for the Second-Line Treatment of Large B-Cell Lymphoma

On April 1, the U.S. Food and Drug Administration (FDA) approved axicabtagene ciloleucel (Yescarta) for adult patients with large B-cell lymphoma (LBCL) who are refractory to first-line chemoimmunotherapy or who experienced relapse within 12 months of first-line chemoimmunotherapy. It is not...

kidney cancer

Several Studies Evaluate Agents in the First-Line, Second-Line, and Later Treatment of Advanced Kidney Cancer

The combination of nivolumab plus cabozantinib achieved a continued survival benefit compared with sunitinib in patients with untreated clear cell metastatic or advanced renal cell carcinoma, according to a final overall survival analysis of the phase III CheckMate 9ER trial.1 Additionally,...

lung cancer

Collaboration Finds International Disparities in Screening, Treatment, and Outcomes for Patients With Lung Cancer

A consensus reached by a lung cancer clinical community within the International Cancer Benchmarking Partnership (ICBP) presented by Lynch et al at the European Lung Cancer Congress (Abstract 196P) has highlighted international disparities in the management and outcomes of patients with lung cancer ...


Therapy Options for MRD-Positive AML

In this video, Drs. Richard Stone, Courtney DiNardo, and Eunice Wang discuss therapy options for minimal residual disease (MRD)-positive acute myeloid leukemia (AML). The case is a 44-year-old man with no past medical history who presents with fevers and fatigue. He is diagnosed with AML and...


Therapy Options for Primary Refractory FLT3-ITD–Positive AML

In this video, Drs. Richard Stone, Courtney DiNardo, and Eunice Wang treatment options for primary refractory FLT3-ITD–positive acute myeloid leukemia (AML). The case is a 60-year-old man with a history of hypertension and hyperlipidemia who presents with fatigue. He is diagnosed with...


Induction Therapy for an Older Patient With IDH1-Mutant AML

In this video, Drs. Richard Stone, Courtney DiNardo, and Eunice Wang discuss the management of newly diagnosed older patients with acute myeloid leukemia (AML). The case is a 75-year-old woman with no past medical history who presents with fever and bone pain. She is diagnosed with AML, and...


Induction Therapy for a Young Patient With AML

This is Part 1 of Updates in Acute Myeloid Leukemia, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Richard Stone, Courtney DiNardo, and Eunice Wang discuss the management of newly diagnosed younger patients with acute myeloid...

lung cancer

Registry Study Shows a Real-World Increase in Biomarker Testing Among Patients With Advanced NSCLC

More than half of patients diagnosed with advanced non–small cell lung cancer (NSCLC) undergo biomarker testing, and this figure has increased over the past 5 years, according to real-world data from a Spanish national registry study reported by Calvo de Juan et al at the European Lung Cancer...


Study Finds Black Patients With Cancer Diagnosed With COVID-19 Have Worse Outcomes Than White Patients

Black patients with cancer experienced significantly worse outcomes after a COVID-19 diagnosis than non-Hispanic White patients, according to findings published by Fu et al in JAMA Network Open. Investigators from the COVID-19 and Cancer Consortium (CCC19) studied the electronic health records of...


Third COVID-19 Vaccine Dose May Improve Immune Response in Patients With Lymphoma

New research has found that the weakened immune systems of patients with lymphoma may improve after they receive a third COVID-19 vaccination. Patients with lymphoma have defects in their immune system that restrict its response to vaccination; despite this, a study published by Lim et al in Nature ...

global cancer care

How ASCO, ECO, and WHO Are Marshalling Resources to Provide Care for Ukrainian Civilians and Refugees With Cancer

Since Russia invaded Ukraine on February 24, the number of attacks on health-care facilities continues to mount. According to the World Health Organization (WHO), as of March 16, there have been 43 attacks on health facilities, including 34 attacks that have directly impacted health facilities and...

pancreatic cancer

Expert Point of View: E. Gabriela Chiorean, MD

The invited discussant of the CodeBreaK 100 data, E. Gabriela Chiorean, MD, Professor of Medicine at the University of Washington and Fred Hutchinson Cancer Research Center, and Clinical Director of the Gastrointestinal Medical Oncology program at Seattle Cancer Care Alliance, found the efficacy of ...

pancreatic cancer

CodeBreaK 100: Sotorasib Shows Activity in KRAS G12C–Mutated Pancreatic Cancer

Promising activity in metastatic pancreatic cancer was shown by sotorasib, an inhibitor of the KRAS G12C mutation, in the phase I/II CodeBreaK 100 study presented by John H. Strickler, MD, Associate Professor of Medicine at Duke University Medical Center, Durham, North Carolina, during the February ...

pancreatic cancer

Expert Point of View: Mandana Kamgar, MD, MPH

The ASCO Post invited Mandana Kamgar, MD, MPH, Assistant Professor of Medicine at the Medical College of Wisconsin, LaBahn Pancreatic Cancer Program, Milwaukee, to comment on the KRYSTAL-1 trial. “The KRYSTAL-1 study in totality is a multiphase and multiarm ongoing study exploring the role of...

pancreatic cancer

KRYSTAL-1: Adagrasib Controls Disease in Gastrointestinal Malignancies Beyond Colorectal Cancer

A disease control rate of 100% was achieved in gastrointestinal cancers treated with the KRAS G12C inhibitor adagrasib in the phase II KRYSTAL-1 trial, presented at the 2022 ASCO Gastrointestinal Cancers Symposium.1 The population included primarily those with pancreatic cancer; other noncolorectal ...

hepatobiliary cancer

Expert Point of View: Anthony El-Khoueiry, MD

Anthony El-Khoueiry, MD, Member of the Section of Gastrointestinal Cancers, Director of the phase I program, and Associate Professor of Clinical Medicine at the Keck School of Medicine of the University of Southern California and USC Norris Comprehensive Cancer Center, said the findings of the...